{"url_path":"/sec/lmat/8-k/2026-06-05/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1158895/0001193125-26-257978-index.html","accession_number":"0001193125-26-257978","cik":"0001158895","ticker":"LMAT","issuer_name":"LEMAITRE VASCULAR INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1158895/0001193125-26-257978-index.html","primary_entity_key":"0001158895","primary_entity_name":"LEMAITRE VASCULAR INC"},"word_count":391,"has_tables":true,"body_markdown":"## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\n(a) On June 2, 2026, LeMaitre Vascular, Inc. (the \"Company\") held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 22,847,798 shares of the Company’s common stock were entitled to vote as of April 6, 2026, the record date for the Annual Meeting, of which 21,336,301 shares were present in person or represented by proxy at the Annual Meeting.\n\n(b) Matters voted upon by the stockholders at the Annual Meeting were: (i) the election of two Class II directors nominated by the Board of Directors for three-year terms; (ii) an advisory vote on the compensation of the Company’s named executive officers; and (iii) the ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for 2026.\n\nSet forth below is information concerning each matter submitted to a vote at the Annual Meeting.\n\nProposal No. 1 – Election of Directors\n\nBy a majority of votes cast, the stockholders elected each of the following two nominees as a Class II director for a term of three years expiring upon the 2029 Annual Meeting of Stockholders or until their successor has been duly elected and qualified. David B. Roberts received a vote of 18,888,412 shares for, 1,250,012 shares withheld and 1,197,877 broker non-votes. John A. Roush received a vote of 14,229,071 shares for, 5,909,353 shares withheld and 1,197,877 broker non-votes.\n\nProposal No. 2 – Advisory Vote on Executive Compensation\n\nBy a majority of votes cast, the stockholders approved, on an advisory basis, the Company's executive compensation by a vote of 19,311,813 shares for and 813,052 shares against, with 13,559 shares abstaining and 1,197,877 broker non-votes.\n\nProposal No. 3 – Ratification of the Selection of Independent Registered Public Accounting Firm\n\n \n\nBy a majority of votes cast, the stockholders ratified the selection of Grant Thornton LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 with a vote of 21,220,412 shares for and 108,474 shares against, with 7,415 shares abstaining.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nLEMAITRE VASCULAR, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 4, 2026\n \n\nBy:\n\n/s/Dorian P. LeBlanc\n\n \n\n \n\n \n\nName: Dorian P. LeBlanc\nTitle: Chief Financial Officer"}